Paragon 28 Inc   (FNA)
Other Ticker:  
Price: $11.7600 $-0.72 -5.769%
Day's High: $11.96 Week Perf: -6.89 %
Day's Low: $ 11.00 30 Day Perf: -7.26 %
Volume (M): 1,146 52 Wk High: $ 19.72
Volume (M$): $ 13,471 52 Wk Avg: $14.42
Open: $11.32 52 Wk Low: $7.95

 Market Capitalization (Millions $) 971
 Shares Outstanding (Millions) 83
 Employees 201
 Revenues (TTM) (Millions $) 207
 Net Income (TTM) (Millions $) -67
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 16

Paragon 28 Inc
The company is a leading medical device company that is exclusively focused on the foot and ankle orthopedic market. They are dedicated to improving patient lives and providing innovative orthopedic solutions, procedural approaches, and instrumentation for a wide range of foot and ankle ailments. The company's comprehensive portfolio of solutions includes surgical implants and disposables, as well as surgical instrumentation. Their products are designed with both the patient and surgeon in mind to improve outcomes, reduce ailment recurrence and complication rates, and make the procedures simpler, consistent, and reproducible. The global market for surgical implants and devices used in foot and ankle procedures is projected to grow at approximately 7% annually to reach approximately $6.0 billion by 2026, representing the fastest growing market within orthopedics. The company believes that growth in the foot and ankle market could accelerate with an increased focus on specialization and with advancements in technology that improve patient outcomes. The foot and ankle market is dominated by a handful of incumbents that operate across the broader medical device and orthopedic markets. The company believes that slow technological and procedural advancement in this market is resulting from a lack of exclusive focus on the foot and ankle market, limited clinical education, understanding and consistent techniques for treating foot and ankle conditions, lack of specialized and clinically focused sales forces, lack of patient specific solutions, lack of advanced technologies, and lack of unbiased research. To disrupt and transform the market, the company focuses exclusively on the foot and ankle market to develop and commercialize differentiated, high-quality orthopedic solutions, advanced procedural approaches, and instrumentation. Their development strategy integrates all aspects of the procedure, including enhancing support systems beyond implants. They rely on an unbiased, clinical, research-first approach to developing new products and each of their systems is designed to deliver an enhanced user-experience throughout the procedure while improving patient outcomes and increasing the reproducibility of results. They deliver their products through a clinically focused sales force and dedicate themselves to medical education to support surgeons, patients, and stakeholders within their organization. The company has developed a comprehensive portfolio of foot and ankle surgical systems and procedural techniques designed to address many of the conditions requiring surgery in the foot and ankle. Each system typically includes numerous plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables. They have designed and currently market 75 product systems with approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. The company has introduced numerous key technological innovations and novel products that have advanced and challenged the status quo in their industry. They are committed to continuously expanding and advancing their portfolio of foot and ankle surgical solutions and bringing next-generation products to market. In addition to their portfolio of products, the company uses Smart 28 to modernize and improve all aspects of foot and ankle treatments by utilizing advanced technologies such as AI, data analytics, patient-specific algorithms, 3-D modeling, and other enabling technologies. Smart 28 aims to further improve patient outcomes and procedure reproducibility, as well as increased patient access to therapies.

   Company Address: 14445 Grasslands Drive Englewood 80112 CO
   Company Phone Number: 912-1332   Stock Exchange / Ticker: NYSE FNA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Paragon 28 Unveils Trio of Minimally Invasive Surgical Systems for Orthopedic Treatments

Published Thu, Feb 1 2024 1:00 PM UTC

Paragon 28 (NYSE: FNA), a global leader in orthopedic medical device innovation, has announced the release of several technology-based surgical systems that aim to improve patient outcomes and speed recovery time with minimally invasive procedures. The company's newly launched PRECISION MIS Bunion System provides surgeons with a guided technique for carrying out a distal me...

Product Service News

Paragon 28 Bolsters Foot and Ankle Surgery with Innovative Solutions

Published Tue, Jan 30 2024 9:43 PM UTC

Paragon 28 Launches Innovative Solutions for Foot and Ankle SurgeryParagon 28, Inc. (NYSE: FNA) recently introduced two groundbreaking products, the FJ2000 Power Console and Burr System, designed specifically for minimally invasive and open foot and ankle procedures. The power console and burr system offer versatility and efficient setup, with three pre-set options for diffe...

Product Service News

Paragon 28 Revolutionizes Tendon Harvesting with the Game-Changing Mister Tendon Harvester System

Published Fri, Jan 26 2024 1:00 PM UTC

In a groundbreaking move towards minimally invasive procedures, medical technology company Paragon 28, Inc. has introduced the Mister Tendon Harvester System. This innovative system allows surgeons to perform distal cuts of the flexor hallucis longus (FHL) or flexor digitorum longus (FDL) tendon through a small incision, facilitating tendon transfer procedures. By enabling b...

Product Service News

Paragon 28 Introduces Bun-Yo-Matic: Revolutionizing Lapidus Bunion Procedures

Published Wed, Jan 17 2024 1:00 PM UTC

Paragon 28, a leading medical device company, is proud to announce the limited market release of its groundbreaking Bun-Yo-Matic Lapidus Clamp System. Marking a significant advancement in the field of bunion surgery, this innovative system has already witnessed successful surgical cases in Orange County, California, and Seattle, Washington. With its ability to simulate weigh...

Product Service News

Paragon 28 Inc. Unleashes the Power of JAWS Great White Staple System: A Game-Changer in Orthopedic Stability

Published Tue, Nov 14 2023 1:00 PM UTC

Paragon 28 Launches JAWS Great White Staple System: Setting a New Standard for Orthopedic Stability
Englewood, Colo. - Paragon 28, Inc. (NYSE: FNA) has taken a significant step forward in the field of orthopedic surgery with the launch of its groundbreaking JAWS Great White Staple System. This innovative product aims to enhance the strength and stability of osteotomy or ...


Paragon 28 Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com